Previous kinetic evaluations of 68 Ga-PSMA-11 for primary prostate cancer have supported the 2T3k or the 2T4k kinetic models, but the findings of this study are consistent with the analysis in high-risk patients established by Ringheim et al. [14, 15, 23]. This evidence concerns the gene FOLH1 and prostate cancer.